Clinical trial
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in…
NCT00398047 · Wake Forest University Health Sciences, Other · Terminated
Key facts
| NCT number | NCT00398047 |
|---|---|
| Title | Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes |
| Official title | Combination of Azacitadine and Hematopoietic Growth Factors for Myelodysplastic Syndrome |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Azacitadine and Hematopoietic Growth Factors |
| Enrollment | 3 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Nov 10, 2006 |
| Last update posted | Sep 6, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: